博济医药：全资子公司获“一种肝脏靶向烷化剂及其应用”专利

Core Viewpoint - The company announced that its wholly-owned subsidiary, Xinglin Traditional Chinese Medicine Technology (Guangzhou) Co., Ltd., has been granted a patent for a liver-targeted alkylating agent and its applications, indicating potential for innovation in cancer treatment [1] Group 1: Patent Details - The patent certificate number is 8613214, with the patent number ZL202211668101.7 [1] - The application date for the patent was December 23, 2022, and the authorization announcement date is set for December 30, 2025 [1] Group 2: Market Implications - The patent has promising applications in treating liver-related cancers, which could enhance the company's competitive edge in the pharmaceutical industry [1] - Although the patent is not expected to have a significant impact on current operating performance, it supports technological innovation [1]